newsfilter
← Latest News
PR Newswire·

NeuroSense Provides Business Update and Progress for the First Half of 2025

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...